Medistim ASA · OSL:MEDI

Medistim ASA — Investor Presentation (April 2020)

38 slides from Medistim ASA's investor presentation, April 2020

  1. Slide 1: Medistim – a niche market leader within ultrasound technology

    Medistim – a niche market leader within ultrasound technology Updated April 2020 Kari E. Krogstad, President and CEO Thomas Jakobsen, CFO

  2. Slide 2: Disclaimer

    2 April 2020 Medistim company presentation Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events or developments that Medistim ASA (“the Company”) expects, projects, believes or anticipates will or may occur in the future

  3. Slide 3: Agenda

    3 April 2020 Medistim company presentation Agenda 1. Medistim today 2. Medical need and technology 3. Market 4. Financial performance 5. Growth strategy

  4. Slide 4: 1. Medistim today

    MED (STIM 1. Medistim today

  5. Slide 5: Medistim history

    5 April 2020 Medistim company presentation MEDISTIM TODAY Medistim history Launch of 2nd generation flowmeter Butterfly™ Launch of 1st Launch of 3rd Launch of new paradigm Launch of generation flowmeter generation flowmeter Flowmetry & Imaging MiraQ™ CardioMed™ VeriQ™ VeriQ C™ 1984 1991 1994 1997 19

  6. Slide 6: Medistim – the leader in Ultrasonic Surgical Guidance & Quality Assessment

    6 April 2020 Medistim company presentation Medistim – the leader in Ultrasonic Surgical Guidance & Quality Assessment Medistim Guidelines • Established 1984 • Epiaortic ultrasound • Headquarter in Oslo, Norway 2007 by ASE, SCA & STS 2011 by ACCF, AHA , AATS, SCA, STS • Global representation 2015 by

  7. Slide 7: 3rd party products contribution to revenues and profit

    7 April 2020 Medistim company presentation MEDISTIM TODAY 3rd party products contribution to revenues and profit Revenues 2019 EBIT 2019 MNOK 363,7 MNOK 89,8 9,9 68,1 Medistim Medistim products products 295,6 79,9 3rd party 3rd party products products 3rd party products represent 19 % of revenues an

  8. Slide 8: 2. Medical need and technology

    2. Medical need and technology

  9. Slide 9: How to ensure a coronary bypass graft is patent? Measure blood flow with TTFM

    9 April 2020 Medistim company presentation How to ensure a coronary bypass graft is patent? – measure blood flow with TTFM TWO PIEZOELECTRIC TRANSDUCERS t1 t2 ANASTOMOSIS ANASTOMOSIS REFLECTOR tΔ = t1 – t2 = proportional to blood flow (Q)

  10. Slide 10: Instant feedback on graft functionality

    10 April 2020 Medistim company presentation Instant feedback on graft functionality - TTFM data before and after graft revision ARTERIAL GRAFT: TTFM of a well functioning LIMA-LAD graft Transit Time Flow Measurement VEIN GRAFT: TTFM of SVG-CX graft showing low flow, After revision (proximal anastomo

  11. Slide 11: Ultrasonic Surgical Guidance & Quality Assessment

    11 April 2020 Medistim company presentation A NEW WORKFLOW – AN EXPANDED VALUE PROPOSITION - A NEW STANDARD OF CARE Ultrasonic Surgical Guidance & Quality Assessment Reduce risk of Optimize graft Verify graft functionality…revise when needed strokes strategy Evaluate ascending Evaluate Assess graft

  12. Slide 12: Surgical guidance & quality assessment is needed in Vascular Surgery as well

    12 April 2020 Medistim company presentation Surgical guidance & quality assessment is needed in Vascular Surgery as well • Guide carotid endarterectomy and assess for technical imperfections • Assess graft patency in peripheral bypass and evaluate anastomosis • Quantify flow for guidance during AV a

  13. Slide 13: Ultrasound systems

    13 April 2020 Medistim company presentation THE PRODUCTS Ultrasound systems TTFM (transit time flow measurement) system TTFM & Ultrasound imaging system PRODUCTS ON THE MARKET: PRODUCTS ON THE MARKET: - MiraQ™ - MiraQ™ - VeriQ™ - VeriQ C™ • Designed for intraoperative TTFM during cardiac, vascular •

  14. Slide 14: MiraQ launch in Europe 2014, USA 2016, China 2017, Japan and Canada 2019

    14 April 2020 Medistim company presentation EXECUTING THE STRATEGY – PRODUCT INNOVATION FOR EASE OF USE MiraQ launch in Europe 2014, USA 2016, China 2017, Japan and Canada 2019 • A platform built for the future • Application specific versions for cardiac and vascular surgery • Focus on ease of use •

  15. Slide 15: Probes are sold as consumables

    15 April 2020 Medistim company presentation THE PRODUCTS Probes are sold as consumables TTFM probes Doppler probe High-frequency ultrasound imaging probe • The flow probes gets attached to the • The doppler X-plore probe is used on • High-frequency probe providing blood vessel and provide fast, the

  16. Slide 16: Alternative business models

    16 April 2020 Medistim company presentation Alternative business models CAPITAL SALES MODEL PAY PER PROCEDURE MODEL LEASE MODEL (USA only, MiraQ excluded) • System is sold as capital equipment • System and probes are placed at the • System is leased out over a period of hospital ‘free of charge’ o F

  17. Slide 17: 3. Market

    MED (STIM 3. Market

  18. Slide 18: Large untapped global coronary bypass market

    18 April 2020 Medistim company presentation Large untapped global coronary bypass market GLOBAL MARKET SIZE MARKET TRENDS • Cardiovascular diseases (CVDs) continue to be the number • > 700,000 CABG1 procedures annually one cause of death globally o 80% arrested heart (on-pump) o Taking an estimated

  19. Slide 19: Huge variation in technology adoption

    19 April 2020 Medistim company presentation CABG Huge variation in technology adoption UK (62M people) • 20.000 procedures RUSSIA (143M people) CHINA (1.3B people) • < 5 % market share • 30.000 procedures • 50.000 procedures • > 40 % market share • 7 % market share USA (314M people) GERMANY(82M peop

  20. Slide 20: Vascular market potential

    20 April 2020 Medistim company presentation Vascular market potential Size of key markets Applications # of procedures Clinical needs (USA, Germany, Nordic) CEA Reduce risk of death and surgery stroke >135 000 Improve cost-effectiveness Peripheral Improve long-term graft bypass patency surgery >200

  21. Slide 21: 4. Financial performance

    MED (STIM 4. Financial performance

  22. Slide 22: Financial highlights

    22 April 2020 Medistim company presentation kNOK 350 000 Financial highlights 300 000 Revenue CAGR = 10.7% (2011 - 201) • 367.7 mill NOK in revenues (2019) 250 000 • Strong revenue and profit growth 200 000 • EBIT margin of 24.7 % 150 000 • Strong cash flow 100 000 • No net long term liabilities 50

  23. Slide 23: Profit and loss 2019

    23 April 2020 Medistim company presentation Profit and loss 2019 Profit & loss 2019 2018 Sales per Quarter (TNOK) All numb ers in NOK 1000 110 000 Sales 363 723 325 890 90 000 Cost of goods sold 80 138 79 381 Salary and sosial expenses 122 016 105 314 70 000 Other operating expenses 53 790 54 857 50

  24. Slide 24: 5. Growth strategy

    MED (STIM 5. Growth strategy

  25. Slide 25: Medistim growth strategy

    25 April 2020 Medistim company presentation EXECUTIVE SUMMARY 1. Convert the routine Flow market to a Flow-and- Medistim growth strategy Imaging market by establishing Surgical Guidance and Quality Assessment as the new standard of care through o Early adopter & KOL support Emerging, o REQUEST study

  26. Slide 26: Implementing the strategy – the REQUEST clinical study

    26 April 2020 Medistim company presentation Implementing the strategy … establishing Surgical Guidance and Quality Assessment as the new standard of care… Now supported by the REQUEST clinical study

  27. Slide 27: REQUEST clinical registry study

    *) Registry for Quality Assessment with Ultrasound imaging and TTFM in cardiac surgery REQUEST*) Clinical Registry Study ____________ Prof. DP Taggart Oxford University ….. Prof. G Di Giammarco University of Chieti ….. Dr. J Puskas Mount Sinai St Luke’s ….. Dr. D Wendt University of Essen ….. Dr. G

  28. Slide 28: Protocol (ClinicalTrials.gov in Feb 2015)

    April 2020 Medistim company presentation EXECUTING THE STRATEGY - THE REQUEST STUDY Protocol (ClinicalTrials.gov in Feb 2015) 1) HF Ultrasound Soft plaque assessment of aorta prior in aorta to manipulation LAD with stenosis 2) HF Ultrasound assessment of arterial conduits and coronary target arterie

  29. Slide 29: Conclusions

    April 2020 Medistim company presentation April 2020: Published in the Journal of Thoracic and EXECUTING THE STRATEGY - THE REQUEST STUDY CardioVascular Conclusions Surgery Surgical Quality In-hospital Guidance Assessment outcome HFUS of aorta, conduit & TTFM & HFUS of MACCE 1,9% coronary target: Ana

  30. Slide 30: Getting closer to the customers in the USA

    30 April 2020 Medistim company presentation Implementing the strategy … achieve routine use… … by getting closer to the customers in the USA

  31. Slide 31: Performance US sales organization

    31 April 2020 Medistim company presentation Performance US sales organization 70 000 CAGR (2013 – 2019) 60 000 = 12.3 % 50 000 40 000 CAGR 2010 -2013 RESULTS 2019 = 6.4 % 30 000 20 000 • Revenues up 11 % in USD and 20.3 % in NOK Number of procedures per year • Total number of procedures up 14.1 % •

  32. Slide 32: Building position in Vascular Surgery

    32 April 2020 Medistim company presentation Implementing the strategy … build and strengthen position... in Vascular Surgery

  33. Slide 33: Vascular sales development

    33 April 2020 Medistim company presentation EXECUTING THE STRATEGY - BUILDING THE VASCULAR MARKET Vascular sales development RESULTS 2019 • 43.3 MNOK in sales revenues, a growth of 18 % • Vascular sales revenues make up 14.6 % of total sales of own products o Nordic countries & Germany are leading m

  34. Slide 34: Outlook…

    34 April 2020 Medistim company presentation Implementing the strategy What to expect next ? Outlook…

  35. Slide 35: Outlook

    35 April 2020 Medistim company presentation Outlook ➢ Accelerated growth in the CABG segment: o Leverage the REQUEST study results ➢ Accelerated growth in the Vascular segment: o Mobilization of sales network ➢ Adding value to the customer experience Seeing is believing o Product and technology deve

  36. Slide 36: Appendix

    36 April 2020 Medistim company presentation Appendix

  37. Slide 37: Balance sheet - Assets

    37 April 2020 Medistim company presentation Balance sheet - Assets Balance sheet 31.12.2019 31.12.2018 All numb ers in NOK 1000 400 000 350 000 Assets 300 000 Intangible assets 40 773 41 944 250 000 Fixed assets 66 835 37 198 200 000 Total intangible and fixed assets 107 608 79 142 150 000 Inventory

  38. Slide 38: Balance sheet - Equity and liability

    38 April 2020 Medistim company presentation Balance sheet - Equity and liability 400 000 Balance sheet 31.12.2019 31.12.2018 All numb ers in NOK 1000 350 000 300 000 Share capital 4 585 4 585 250 000 Premium fund 44 172 44 172 Other equity 188 104 157 955 200 000 Total equity 236 861 206 712 150 000

Medistim — Investor Presentation (April 2020) on 6ix